The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Tempus
Effect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer.
 
Alvaro Quintanal-Villalonga
Honoraria - AstraZeneca
Research Funding - Duality Biologics; Foghorn Therapeutics; Jazz Pharmaceuticals
 
Kenta Kawasaki
No Relationships to Disclose
 
Esther Redin
No Relationships to Disclose
 
Swanand Rakhade
No Relationships to Disclose
 
Vidushi Durani
No Relationships to Disclose
 
Amin Sabet
No Relationships to Disclose
 
Wouter Karthaus
No Relationships to Disclose
 
Samir Zaidi
No Relationships to Disclose
 
Yingqian A. Zhan
No Relationships to Disclose
 
Parvathy Manoj
No Relationships to Disclose
 
Harsha Sridhar
No Relationships to Disclose
 
Hong Zhong
No Relationships to Disclose
 
Barbara Mello
No Relationships to Disclose
 
Metamia Ciampricotti
No Relationships to Disclose
 
Umesh Bhanot
No Relationships to Disclose
 
Michael C. Haffner
Research Funding - Merck
 
Nicholas D. Socci
Employment - Bellevue Hospital (I); Memorial Sloan-Kettering Cancer Center
Consulting or Advisory Role - Simons Foundation
 
Helena Alexandra Yu
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen; Novocure; Taiho Oncology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Systimmune (Inst)
Other Relationship - Astellas Pharma
 
Joseph Minhow Chan
Research Funding - AstraZeneca
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Auron Therapeutics; Bridge Medicines; D2G Oncology; Daiichi Sankyo/UCB Japan; DISCO; Earli; Genentech/Roche; Harpoon Therapeutics; Jazz Pharmaceuticals; Kowa; Merck
Research Funding - Daiichi Sankyo (Inst); Merck (Inst); Roche/Genentech (Inst)